Molecure S.A.

Equities

MOC

PLONCTH00011

Biotechnology & Medical Research

Market Closed - Warsaw S.E. Other stock markets 11:55:42 2024-05-15 EDT			5-day change	1st Jan Change
14.72 ^PLN	-4.29%		+1.66%	-24.51%

03-22	Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	CI
01-16	Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	CI

OncoArendi Therapeutics - INVITATION TO TENDER NO 7/2022-DUBs - Successive delivery of selected cytokines

March 03, 2022 at 09:30 am

In connection with the implementation of the project:

DUBs: 'SEARCH AND DEVELOPMENT OF DEUBIQUITINASE INHIBITORS FOR USE IN ANTICANCER IMMUNOTHERAPY' (POIR.01.01.01-00-0615/19) co-financed by EU funds, as well as in connection with the obligation to apply the principle of competitiveness

OncoArendi Therapeutics SA invites you to submit bids for:

Successive delivery of selected cytokines, delivery of 3 (or less) x per week for a period of 9 months from the date of validity of the contract.

Contact:

OncoArendi Therapeutics SA

Dowborczykow 30/34, 90-019 od

Mobile: +48 518 159 494

E: m.kaminski@oncoarendi.com

About us

OncoArendi Therapeutics (OAT) is an innovative biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for neoplastic and inflammatory diseases.

Latest news about Molecure S.A.

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	03-22	CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	01-16	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment	23-07-24	MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01	23-07-24	CI
Molecure S.A. announced that it has received PLN 49.968 million in funding	23-07-20	CI
Poland's Molecure Files Investigational New Drug Application with US FDA for Pulmonary Sarcoidosis Drug	23-06-23	MT
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Poland's Molecure Doses First Patient in Cancer Treatment Trial	23-03-08	MT
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer	23-03-08	CI
Molecure S.A. Announces Management Changes	23-01-03	CI
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland	22-11-28	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Molecure S.A.(WSE:MOC) dropped from S&P Global BMI Index	22-09-19	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
ONCOARENDI THERAPEUTICS S.A will Change its Name to Molecure S.A	22-04-04	CI
OncoArendi Therapeutics S.A. Announces A License Option Agreement with University of Michigan	22-03-11	CI
OncoArendi Therapeutics S.A. Announces Board Appointments	22-01-31	CI
OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer	22-01-27	CI
OncoArendi Therapeutics S.A. Announces Board Changes	22-01-14	CI
OncoArendi Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-28	CI
Molecure S.A.(WSE:MOC) added to S&P Global BMI Index	21-09-20	CI

Chart Molecure S.A.

Duration

Period

More charts

Company Profile

Oncoarendi Therapeutics SA is a Poland-based biopharmaceutical company . The Company is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The Company's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The Company has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

Sector

Biotechnology & Medical Research

Calendar

2024-09-26 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.72 PLN

Average target price

34 PLN

Spread / Average Target

+130.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECURE S.A.	-24.51%	65.58M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	111B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.58%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.54B
LEGEND BIOTECH CORPORATION	-23.95%	8.09B

Bio Therapeutic Drugs